The potential use of folate and its derivatives in treating psychiatric disorders: A systematic review

• Published in: Biomedicine & pharmacotherapy 2022-02, Vol.146, p.112541-112541, Article 112541
• Main Authors: Lam, Nelson Siu Kei, Long, Xin Xin, Li, Xuegang, Saad, Mirette, Lim, Florence, Doery, James CG, Griffin, Robert C., Galletly, Cherrie
• Format: Article
• Language: English
• Subjects: Attention Deficit Disorder with Hyperactivity - drug therapy; Attention deficit hyperactive disorder; Autism; Autism Spectrum Disorder - drug therapy; Bipolar affective disorder; Bipolar Disorder - drug therapy; Depressive Disorder, Major - drug therapy; Female; Folate; Folate receptor alpha antibodies; Folic acid; Folic Acid - therapeutic use; Folinic acid; Humans; L-Methylfolate; Major depressive disorder; Mental disorder; Methylenetetrahydrofolate reductase polymorphism; Post-menopausal depression; Postpartum depression; Reduced folate carrier; Schizophrenia
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2021.112541

To examine the strengths and limitations of existing data to provide guidance for the use of folate supplements as treatment, with or without other psychotropic medications, in various psychiatric disorders. To identify area for further research in terms of the biosynthesis of mechanism of folate and genetic variants in metabolic pathway in human. A systematic review of published literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to assess whether folate supplements are beneficial in certain psychiatric disorders (depression, bipolar disorder, schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder). Methodology of this review is registered with Prospero (Registration number CRD 42021266605). Eligible studies were identified using a systematic search of four electronic databases: Embase, Pubmed, PsycINFO, and Cochrane. The search strategy covered the time period from 1974 to August 16th, 2021. Therefore, this review examines randomized control trials or open-label trials completed during this period. We identified 23 studies of folate supplements in various psychiatric disorders for critical review. Of these, 9 studies investigated the efficacy of folate supplements in major depressive disorders, 5 studies in schizophrenia, 6 studies in autism spectrum disorder, 2 studies in bipolar affective disorder and 1 study in attention deficit hyperactive disorder. The most consistent finding association of oral levomefolic acid or 5-methylfolate with improvement in clinical outcomes in mental health conditions as mentioned above, especially in major depressive disorder (including postpartum and post-menopausal depression), schizophrenia, autism spectrum disorder, attention deficit hyperactivity disorder and bipolar affective disorder. Folate supplements were well tolerated. Our results are not representative of all types of studies such as case reports or case series studies, nor are they representative of the studies conducted in languages that are not in English or not translated in English. Increasing evidence from clinical trials consistently demonstrate folate supplements, especially levomefolic acid or 5-methylfolate, may improve clinical outcomes for certain psychiatric diseases, especially as an adjunct pharmacotherapy with minimal side effects. [Display omitted] •Folate supplements especially levomefolic acid (L-5-methylfolate) demonstrated improvement in clinical o